Recruiting
Phase 2

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Sponsor:

Joseph Tuscano

Code:

NCT04450173

Conditions

Ann Arbor Stage II Follicular Lymphoma

Ann Arbor Stage III Follicular Lymphoma

Ann Arbor Stage IV Follicular Lymphoma

Grade 1 Follicular Lymphoma

Grade 2 Follicular Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

Obinutuzumab

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information